Turning Clinical Evidence Into a Strategic Advantage with Ethan Drower

A medical device is only as strong as the evidence behind it. Innovation may spark the idea, but clinical evidence, regulatory strategy, and a clear path to adoption are what transform technology into a solution that reaches patients and lasting impact.

For many medtech companies, evidence generation is viewed as a regulatory requirement, a necessary step toward approval. However, when approached strategically, clinical evidence becomes much more than documentation. It can shape fundraising, commercialization strategies, reimbursement decisions, and company value.

Ethan Drower, Co-Founder and CEO of CiteMed, experienced this challenge firsthand. With a background in software and technology, Ethan entered medtech after recognizing the growing complexity companies faced navigating evolving regulatory requirements. His father, a quality and regulatory expert, was working through the transition to changing European medical device regulations and the increasing demand for stronger clinical evidence. What started as a conversation around a kitchen table became the foundation for CiteMed, a platform designed to help medical technology companies better manage, understand, and leverage clinical evidence throughout the product lifecycle. 

Solving a growing challenge in medtech

As regulatory expectations increased, companies faced greater pressure to generate stronger clinical evidence through literature reviews, documentation, and analysis. Recognizing an opportunity to improve this process, Ethan combined his software background with his father’s regulatory experience to explore how technology could make evidence generation more efficient. CiteMed began by helping companies complete evidence reviews and evolved into a broader clinical evidence management solution.

While regulatory compliance was the initial driver, Ethan quickly recognized that clinical evidence could create value beyond submissions and documentation. It can influence product claims, guide commercialization strategies, strengthen investor conversations, and demonstrate value to potential partners or acquirers. Ethan explained, “We started to realize that evidence, when properly kept, is an incredible asset for a medtech organization.” 

Today, CiteMed’s Evidence Cloud platform helps organizations collect, organize, review, and maintain clinical evidence in a centralized system. Instead of treating evidence as a one-time requirement, companies can build an ongoing resource that supports better decision-making and identifies stronger opportunities for their products. Ethan explained, “It’s not just about conducting your literature review and forgetting about it. It’s accumulating this centralized store of evidence that is now searchable across your devices and your claims.”

Building trust through traceability

Managing clinical evidence requires more than collecting information. Companies must understand where evidence comes from, how it supports claims, and how decisions are made. For Ethan, transparency and traceability are essential to building effective technology solutions for medtech. While automation can improve efficiency, experts still need confidence in the process and visibility into the reasoning behind recommendations. This approach ensures technology supports expert judgment.

Why this matters

Ethan’s journey highlights an important lesson for medtech innovators: clinical evidence is not simply a regulatory obligation. It is a strategic advantage. One of the biggest challenges Ethan sees among startups is understanding how regulatory strategy impacts company value. A strong device alone is not enough; investors and partners also consider approval pathways, evidence requirements, and whether a company can support future claims. Building an evidence strategy early can help prevent costly challenges and create a foundation for fundraising and adoption.

What to watch

The future of medtech belongs to companies that recognize clinical evidence as a foundation for innovation. As healthcare technology continues to advance, the ability to efficiently manage, understand, and apply evidence will become a critical advantage in bringing meaningful solutions to patients and providers. Ethan’s advice for founders is clear: regulatory strategy, evidence generation, and business success are deeply connected. “If you could be good at defining your claims and maximizing them, it’s a huge competitive advantage.”

By understanding what their evidence supports and how it shapes their market strategy, companies can strengthen their positioning, improve decision-making, and create greater value. Building a medical device is not only about creating a solution. It is about proving its value, defining its impact, and ensuring it can successfully move toward adoption. In medtech, the strongest innovations are not defined only by what a technology can do. They are defined by the evidence, strategy, and confidence that demonstrate why they matter.

To learn more, listen to the full Project Medtech Podcast episode with Ethan Drower, Co-Founder and CEO of CiteMed: https://www.projectmedtech.com/projectmedtechpodcast/episode/1fb024bf/episode-268-ethan-drower-co-founder-ceo-of-citemed-breaking-down-barriers-with-clinical-evidence